Table 3.

Ponatinib’s clinical trials in other cancer types

Phase	Clinical trial study	Patient criteria	Status	Trial number
II	Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions	Patients with advanced biliary cancer that is refractory or intolerant to gemcitabine- or fluoropyrimidine-based therapy with FGFR2 fusions	Ongoing, not recruiting participants	NCT02265341
II	Ponatinib for Patients Whose Advanced Solid Tumour Cancer Has Activating Mutations Involving FGFR1-4, RET and KIT	Patients with refractory metastatic solid tumor with activating genomic alterations in FGFR, RET, and/or KIT	Recruiting patients	NCT02272998
II	Ponatinib in Advanced NSCLC with RET Translocations	Advanced NSCLC patients with RET mutation	Recruiting patients	NCT01813734
II	Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions	Patients with advanced biliary cancer that is refractory or intolerant to gemcitabine- or fluoropyrimidine-based therapy with FGFR2 fusions	Ongoing, not recruiting participants	NCT02265341
II	Ponatinib for Patients Whose Advanced Solid Tumour Cancer Has Activating Mutations Involving FGFR1-4, RET and KIT	Patients with refractory metastatic solid tumor with activating genomic alterations in FGFR, RET, and/or KIT	Recruiting patients	NCT02272998
II	Ponatinib in Advanced NSCLC with RET Translocations	Advanced NSCLC patients with RET mutation	Recruiting patients	NCT01813734
II	Study of Ponatinib in Patients with Lung Cancer Preselected Using Different Candidate Predictive Biomarkers	Patients with stage III–IV lung cancer including NSCLC and who have been previously tested for both EGFR mutations and anaplastic lymphoma kinase	Active, not recruiting patients	NCT01935336
II	POETIG Trial – Ponatinib After Resistance to Imatinib in GIST	GIST patients with failure or intolerance to imatinib or histologically confirmed metastatic and/or unresectable GIST harboring a primary KIT or PDGFRA mutation	Recruiting patients	NCT03171389
I/II	Trial of Trametinib and Ponatinib in Patients with KRAS Mutant Advanced Non-Small Cell Lung Cancer	Patients with histologically or cytologically proven diagnosis of advanced lung adenocarcinoma harboring KRAS mutation	Recruiting patients	NCT03704688

Abbreviations: GIST, gastrointestinal stromal tumor; NSCLC, non-small-cell lung cancer.